Effect and risk of AEE788, a dual tyrosine kinase inhibitor, on regeneration in a rat liver resection model

European Surgical Research

Volumn 44, Issue 2, 2010, Pages 82-95

  Deng, M ^a   Huang, H ^a   Dirsch, O ^b   Dahmen, U ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

AEE788; Colorectal cancer liver metastasis; Epidermal growth factor receptor; Liver resection; Regeneration; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; COMPLEMENTARY DNA; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SOLVENT; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; LYMPH NODE METASTASIS; MICROCIRCULATION; NONHUMAN; PARTIAL HEPATECTOMY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SPECTROSCOPY; TISSUE REGENERATION; WESTERN BLOTTING;

ANIMALS; BODY WEIGHT; CELL DIVISION; COLORECTAL NEOPLASMS; HEPATECTOMY; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; LIVER REGENERATION; MALE; MICE; MITOTIC INDEX; NEOPLASM METASTASIS; ORGAN SIZE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PURINES; RATS; RATS, INBRED LEW; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 74249121889     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275818     Document Type: Article

References (45)

1. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH: Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007; 14: 786-794.
2. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-722, discussion 722-724.
3. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM, Nagorney DM: Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246: 183-191.
4. Fausto N, Campbell JS, Riehle KJ: Liver regeneration. Hepatology 2006; 43:S45-S53.
5. Stolz DB, Mars WM, Petersen BE, Kim TH, Michalopoulos GK: Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res 1999; 59: 3954-3960.
6. Chun YS, Laurent A, Maru D, Vauthey JN: Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009; 10: 278-286.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
8. Wilson RH: Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist 2006; 11: 1018-1024.
9. Overman MJ, Hoff PM: EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum 2007; 50: 1259-1270.
10. Van Buren G, Yang AD, Dallas NA, Gray MJ, Lim SJ, Xia L, Fan F, Somcio R, Wu Y, Hicklin DJ, Ellis LM: Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 2008; 26: 1836-1842.
11. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G: AEE788: a dual family epidermal growth factor receptor/ ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
12. Yokoi K, Thaker PH, Yazici S, Rebhun RR, Nam DH, He J, Kim SJ, Abbruzzese JL, Hamilton SR, Fidler IJ: Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005; 65: 3716-3725.
13. Kuwai T, Nakamura T, Sasaki T, Kitadai Y, Kim JS, Langley RR, Fan D, Wang X, Do KA, Kim SJ, Fidler IJ: Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis 2008; 25: 477-489.
14. Okamoto K, Neureiter D, Alinger B, Meissnitzer M, Sass G, Schmitz V, Di Fazio P, Wissniowski T, Gahr S, Hohenstein B, Kaufmann B, Schlosser A, Haus U, Hahn EG, Herold C, Ocker M: The dual EGF/ VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol 2008; 33: 733-742.
15. Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, Fidler IJ: Targeting receptor tyrosine kinase on lymphatic endothelial cells for the therapy of colon cancer lymph node metastasis. Neoplasia 2006; 8: 747-757.
16. Madrahimov N, Dirsch O, Broelsch C, Dahmen U: Marginal hepatectomy in the rat: from anatomy to surgery. Ann Surg 2006; 244: 89-98.
17. Meco D, Riccardi A, Servidei T, Brueggen J, Gessi M, Riccardi R, Dominici C: Antitumor activity of imatinib mesylate in neuroblastoma xenografts. Cancer Lett 2005; 228: 211-219.
18. Deng M, Kleinert R, Huang H, He Q, Madrahimova F, Dirsch O, Dahmen U: Statistical and economical efficiency in assessment of liver regeneration using defined sample size and selection in combination with a fully automated image analysis system. J Histochem Cytochem 2009; 57: 1075-1085.
19. Xing W, Deng M, Zhang J, Huang H, Dirsch O, Dahmen U: Quantitative evaluation and selection of reference genes in a rat model of extended liver resection. J Biomol Tech 2009; 20: 109-115.
20. Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-782.
21. Washington K, Lane KL, Meyers WC: Nodular regenerative hyperplasia in partial hepatectomy specimens. Am J Surg Pathol 1993; 17: 1151-1158.
22. Skarpen E, Oksvold MP, Grosvik H, Widnes C, Huitfeldt HS: Altered regulation of EGF receptor signaling following a partial hepatectomy. J Cell Physiol 2005; 202: 707-716.
23. Fabrikant JI: The kinetics of cellular proliferation in regenerating liver. J Cell Biol 1968; 36: 551-565.
24. Merle P, Chevallier M, Levy R, Maisonnas M, Terradillos O, Ahmed SNS, Trepo C, Buendia MA, Vitvitski-Trepo L: Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice. J Hepatol 2001; 34: 562-569.
25. Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, Fidler IJ: Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate 2005; 65: 203-215. (Pubitemid 41443725)
26. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN: Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005; 4: 101-112.
27. Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958; 18: 853-856.
28. Harada K, Shiota G, Kawasaki H: Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999; 19: 318-325.
29. Diasio RB, Fourie J: Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs 2006; 66: 1441-1463.
30. Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-1354.
31. Huitfeldt HS, Skarpen E, Lindeman B, Becher R, Thrane EV, Schwarze PE: Differential distribution of Met and epidermal growth factor receptor in normal and carcinogen- treated rat liver. J Histochem Cytochem 1996; 44: 227-233.
32. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Lee DC, Prieto J, Avila MA: Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 2005; 128: 424-432.
33. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K: Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159-165.
34. Ferry DR, Anderson M, Beddard K, Tomlinson S, Atherfold P, Obszynska J, Harrison R, Jankowski J: A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13: 5869-5875.
35. DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC: Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood 2006; 108: 3674-3681.
36. Pennell NA, Lynch TJ Jr.: Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist 2009; 14: 399-411.
37. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812.
38. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, von Pawel J, Temel J, Siena S, Soulieres D, Saltz L, Leyden J: HER1/ EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10: 345-356.
39. Park YW, Younes MN, Jasser SA, Yigitbasi OG, Zhou G, Bucana CD, Bekele BN, Myers JN: AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 2005; 11: 1963-1973.
40. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El Naggar AK, Myers JN: Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 2006; 5: 2696-2705.
41. Shelly D, Tevatia MS, Praharaj AK, Mehta A, Harish S, Baskaran V: Nodular regenerative hyperplasia of liver. Indian J Pathol Microbiol 2008; 51: 78-80.
42. Wang HM, Lo GH, Hsu PI, Lin CK, Chan HH, Chen WC, Lai KH, Wang BW, Lin SL: Nodular regenerative hyperplasia of the liver. J Chin Med Assoc 2008; 71: 523-527.
43. Hubert C, Sempoux C, Horsmans Y, Rahier J, Humblet Y, Machiels JP, Ceratti A, Canon JL, Gigot JF: Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int 2007; 27: 938-943.
44. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001; 21: 499-512.
45. Takada T, Weiss HM, Kretz O, Gross G, Sugiyama Y: Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolo-pyrimidine class, and its main metabolite, ACU154. Drug Metab Dispos 2004; 32: 1272-1278.